NCT05520398

Brief Summary

The aim of this study is to understand why patients with obsessive-compulsive disorder (OCD) fail in therapy. To understand the neural mechanisms involved in exposure therapy that support success and clinical improvement in order to improve therapy outcomes for OCD patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 10, 2021

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

August 26, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 29, 2022

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

December 19, 2024

Status Verified

December 1, 2024

Enrollment Period

4.1 years

First QC Date

August 26, 2022

Last Update Submit

December 16, 2024

Conditions

Obsessive-Compulsive Disorder

Outcome Measures

Primary Outcomes (2)

  • Yale-Brown obsessive compulsive scale (Y-BOCS)

    The Y-BOCS is a 10-item scale used to assess symptom severity in OCD.

    3 - 9 months

  • Decision making and learning tasks

    Computer-based behavioural task developed by the investigators to understand decision making in OCD.

    3 - 9 months

Secondary Outcomes (10)

  • Patient EX/RP Adherence Scale (PEAS)

    3 - 9 months

  • Short form of Obsessive Beliefs Questionnaire (OBQ)

    3 - 9 months

  • Brief Experiential Avoidance Questionnaire (BEAQ)

    3 - 9 months

  • International Cognitive Ability Resource (ICAR16)

    3 - 9 months

  • Worry Domains Questionnaire - Short Form (WDQ-SF)

    3 - 9 months

  • +5 more secondary outcomes

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with obsessive-compulsive disorder (OCD)

You may qualify if:

  • Diagnosis of obsessive-compulsive disorder (OCD)
  • Fluent in written and spoken English
  • Normal/corrected to normal vision
  • Expecting to start OCD therapy

You may not qualify if:

  • Autism spectrum disorder, psychosis, schizophrenia, addiction, substance abuse, bipolar, hoarding, or Tourette disorder
  • Hearing conditions: tinnitus, ear inflammation, hearing sensitivity, hearing loss, requires hearing aids
  • Colour blindness
  • Severe learning disabilities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Max Planck UCL Centre for Computational Psychiatry and Ageing Research

London, WC1B 5EH, United Kingdom

RECRUITING

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Condition Hierarchy (Ancestors)

Anxiety DisordersMental Disorders

Study Officials

  • Tobias Hauser, PhD

    University College, London

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tricia Seow, PhD

CONTACT

+44-(0)203-1087538t.seow@ucl.ac.uk

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2022

First Posted

August 29, 2022

Study Start

November 10, 2021

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

December 19, 2024

Record last verified: 2024-12

Locations

GB(1)